Juggling the impact of disease, treatment, study participation on patients’ lives
Ville Varmavuo, MD, PhD
Kotka, Chief Medical Officer in Education,Internal Medicine, Finland
We all realize myeloma has a major impact on patients’ lives. But also treatments and participating in clinical studies can have a major influence. To what extent is this being discussed with patients?
This e-learning module zooms in on juggling the impact of the disease, treatment and/or participation in clinical studies on the quality of life.
Approximate time: 1 hour
Module 3: Juggling the impact of disease, treatment, study participation on patients’ lives
Accredited for 1 CME point
Inger Nijhof, MD, PhD
Hematologist,
St. Antonius Hospital,
Department of Internal Medicine,
The Netherlands
Fredrik Schjesvold, MD, PhD
Hematologist,
Oslo Myeloma Center,
Department of Hematology,
Norway
Isabelle Vande Broek, MD, PhD
Hematologist,
Vitaz, Sint-Niklaas,
Department of Oncology & Hematology,
Belgium
Agoston Gyula Szabo , MD
Hematologist,
Righospitalet Copenhagen,
Department of Hematology,
Denmark
Ville Varmavuo, MD, PhD
Chief Medical Officer in Education,
Kotka,
Internal Medicine,
Finland
Prof. Xavier Leleu, MD, PhD
Hematologist,
Academic Hospital of Poitiers,
France
Valdas Peceliunas, MD
Hematologist,
Vilnius University Hospital Santaros Klinikos,
Department of Hematology,
Lithuania
Accreditation
Accreditation for this e-learning has been granted for 3 points by:
European Accreditation Council for Continuing Medical Education (EACCME)
Obtain CME points
To obtain CME points, you must answer at least 70% of the questions in the final test correctly. If you have a lower score, you can retake the final test twice more. You can pause the e-learning and then resume where you paused.
Clinical cases
Throughout the e-learning challenging clinical cases from daily practice are being presented by the International Expert Panel.
